JP2024518434A5 - - Google Patents
Info
- Publication number
- JP2024518434A5 JP2024518434A5 JP2023568501A JP2023568501A JP2024518434A5 JP 2024518434 A5 JP2024518434 A5 JP 2024518434A5 JP 2023568501 A JP2023568501 A JP 2023568501A JP 2023568501 A JP2023568501 A JP 2023568501A JP 2024518434 A5 JP2024518434 A5 JP 2024518434A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- het
- group
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021092256 | 2021-05-08 | ||
| CNPCT/CN2021/092256 | 2021-05-08 | ||
| PCT/CN2022/091065 WO2022237626A1 (en) | 2021-05-08 | 2022-05-06 | Substituted spiro derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024518434A JP2024518434A (ja) | 2024-05-01 |
| JP2024518434A5 true JP2024518434A5 (https=) | 2025-05-14 |
Family
ID=76159225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023568501A Pending JP2024518434A (ja) | 2021-05-08 | 2022-05-06 | 置換スピロ誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4334310A1 (https=) |
| JP (1) | JP2024518434A (https=) |
| KR (1) | KR20240006542A (https=) |
| CN (1) | CN117321049A (https=) |
| AU (1) | AU2022272692A1 (https=) |
| BR (1) | BR112023023154A2 (https=) |
| CA (1) | CA3215379A1 (https=) |
| MX (1) | MX2023013174A (https=) |
| WO (1) | WO2022237626A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
| US20240417405A1 (en) * | 2021-05-08 | 2024-12-19 | Janssen Pharmaceutica Nv | Substituted Spiro Derivatives |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102984941B (zh) | 2009-09-04 | 2016-08-17 | 密执安大学评议会 | 用于治疗白血病的组合物和方法 |
| WO2014164543A1 (en) | 2013-03-13 | 2014-10-09 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| HK1246593A1 (zh) | 2015-06-04 | 2018-09-14 | Kura Oncology, Inc. | 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物 |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| AU2016378579A1 (en) | 2015-12-22 | 2018-06-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-MLL interaction |
| PL3429591T3 (pl) | 2016-03-16 | 2023-07-17 | Kura Oncology, Inc. | Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania |
| PH12018501955B1 (en) | 2016-03-16 | 2024-01-24 | Kura Oncology Inc | Bridged bicyclic inhibitors of menin-mll and methods of use |
| JP6991585B2 (ja) | 2016-05-02 | 2022-01-12 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | メニン阻害剤としてのピペリジン |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| WO2017214367A1 (en) * | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| CA3033020A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-mll interaction |
| CA3033239A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| AU2017326006B2 (en) | 2016-09-16 | 2021-10-28 | Vitae Pharmaceuticals, LLC. | Inhibitors of the menin-MLL interaction |
| WO2018109088A1 (en) | 2016-12-15 | 2018-06-21 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-mll interaction |
| WO2018175746A1 (en) | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Methods for treating hematological malignancies and ewing's sarcoma |
| WO2018226976A1 (en) | 2017-06-08 | 2018-12-13 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| EP3684361A4 (en) | 2017-09-20 | 2021-09-08 | Kura Oncology, Inc. | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING |
| JP7307729B2 (ja) | 2017-12-20 | 2023-07-12 | ヤンセン ファーマシューティカ エヌ．ベー． | メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤 |
| KR102779601B1 (ko) * | 2018-08-27 | 2025-03-12 | 스미토모 파마 가부시키가이샤 | 광학 활성인 아자비시클로환 유도체 |
| JP2022503792A (ja) | 2018-09-26 | 2022-01-12 | クラ オンコロジー，インク． | メニン阻害剤を用いた血液悪性腫瘍の処置 |
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
| CN111297863B (zh) | 2020-03-30 | 2021-06-25 | 四川大学华西医院 | menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用 |
| US20240417405A1 (en) * | 2021-05-08 | 2024-12-19 | Janssen Pharmaceutica Nv | Substituted Spiro Derivatives |
-
2022
- 2022-05-06 CA CA3215379A patent/CA3215379A1/en active Pending
- 2022-05-06 JP JP2023568501A patent/JP2024518434A/ja active Pending
- 2022-05-06 KR KR1020237038500A patent/KR20240006542A/ko active Pending
- 2022-05-06 MX MX2023013174A patent/MX2023013174A/es unknown
- 2022-05-06 EP EP22725155.0A patent/EP4334310A1/en active Pending
- 2022-05-06 CN CN202280033667.4A patent/CN117321049A/zh active Pending
- 2022-05-06 AU AU2022272692A patent/AU2022272692A1/en not_active Abandoned
- 2022-05-06 BR BR112023023154A patent/BR112023023154A2/pt not_active Application Discontinuation
- 2022-05-06 WO PCT/CN2022/091065 patent/WO2022237626A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024518434A5 (https=) | ||
| JP2024521879A5 (https=) | ||
| JP2024518425A5 (https=) | ||
| IL322109A (en) | Tricyclic compounds for cancer treatment | |
| US20260098036A1 (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| JP2019510798A5 (https=) | ||
| EP2101759B1 (en) | Methods of using mek inhibitors | |
| KR101345920B1 (ko) | 키나제 억제제로서의 피콜린아미드 유도체 | |
| AU2017269870A1 (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
| EP3713923B1 (en) | 2-phenylpyrimidine-4-carboxamides as ahr inhibitors | |
| UA118965C2 (uk) | 6-(5-гідрокси-1н-піразол-1-іл)нікотинамідні інгібітори рнd | |
| ES2462522T3 (es) | Heterociclilbencilpirazoles sustituidos y uso de los mismos | |
| JP6726681B2 (ja) | Ｐｈｄ阻害剤としての縮合二環式ヘテロアリール誘導体 | |
| EP2499115A1 (en) | Hepatitis c virus inhibitors | |
| WO2025085815A1 (en) | Protac compounds binding keap1 ubiquitin ligase for targeted protein degradation | |
| JP2015514808A5 (https=) | ||
| WO2025083472A2 (en) | Protac compounds binding keap1 ubiquitin ligase for targeted protein degradation | |
| JP2018522929A5 (https=) | ||
| JP2024518497A5 (https=) | ||
| JP2018048121A (ja) | キナーゼ阻害剤としての新規環置換ｎ−ピリジニルアミド | |
| JP2020500866A5 (https=) | ||
| EP3219329A1 (en) | Combinations of copanlisib | |
| US20210128572A1 (en) | Combination of atr kinase inhibitors with parp inhibitors | |
| EP3209660A1 (en) | 1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors | |
| JP2017519760A5 (https=) |